384 results on '"Burns, Christopher J."'
Search Results
2. Author Correction: CIS is a potent checkpoint in NK cell–mediated tumor immunity
3. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells
4. Author Correction: CIS is a potent checkpoint in NK cell–mediated tumor immunity
5. HBO1 is required for the maintenance of leukaemia stem cells
6. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
7. A constricted opening in Kir channels does not impede potassium conduction
8. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1
9. Table 2 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
10. Data from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
11. Supplementary Tables S1, S3-S7, Supplementary Material and Methods, and Supplementary Figure Legends from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
12. Figure S1-S6 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
13. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9
14. Medicinal chemists: Central to drug discovery
15. CIS is a potent checkpoint in NK cell–mediated tumor immunity
16. Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
17. Abstract CT511: A phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers
18. The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In Vivo
19. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
20. Cell-based treatments for diabetes
21. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
22. Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
23. 89 The Effect of Trauma Center Status and Burn Verification Process on Burn Patient Outcomes
24. The Use of JAK-Specific Inhibitors as Chemical Biology Tools
25. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
26. Solution- and solid-phase synthesis of components for tethered bilayer membranes
27. 21 Racial Disparities in Outcomes After Burn Injury in a Universally Insured Military Population
28. The bioactive conformation of human parathyroid hormone. Structural evidence for the extended helix postulate
29. Venous Thromboembolic Disease in Colorectal Patients
30. Generation of insulin-expressing cells from mouse embryonic stem cells
31. 37 The identification of novel CSF-1 target genes in human macrophages
32. Beta-cell replacement technologies: the potential of stem cells
33. The role of cytosolic phospholipase [A.sub.2] in insulin secretion
34. A tethered bilayer sensor containing alamethicin channels and its detection of amiloride based inhibitors
35. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
36. HBO1 is required for the maintenance of leukaemia stem cells
37. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
38. Chemical Industry Update: Nestle and Phosphagenics Commence Phospha E Phase 2 Trial
39. Chemical Industry Update: CFCL Wins Environmental Award
40. Chemical Industry Update: Orica Acquires Excel Mining Systems
41. Chemical Industry Update: BioProspect Wins Exclusive Licence to Develop Solagran Products
42. Chemical Industry Update: Starpharma's DNT to Develop Water Purification Technology
43. Chemical Industry Update: Bionomics to Develop Cancer Drug Target with Support from the Cancer Therapeutics CRC
44. Chemical Industry Update: Phase II Trial Finds Pharmaxis' Bronchitol Effective
45. Chemical Industry Update
46. Chemical Industry Update
47. Analogues of Human Parathyroid Hormone (1–31)NH 2: Further Evaluation of the Effect of Conformational Constraint on Biological Activity
48. Chemical Industry Update
49. Obituaries: Melvyn Gill FRACI 1946-2004
50. Chemical Industry Update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.